No connection

Search Results

BFRI vs TNON

BFRI
Biofrontera Inc.
BEARISH
Price
$0.86
Market Cap
$10.0M
Sector
Healthcare
AI Confidence
92%
TNON
Tenon Medical, Inc.
BEARISH
Price
$0.80
Market Cap
$9.0M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
BFRI
--
TNON
--
Forward P/E
BFRI
-3.72
TNON
-1.28
P/B Ratio
BFRI
-3.85
TNON
4.41
P/S Ratio
BFRI
0.27
TNON
2.29
EV/EBITDA
BFRI
-0.65
TNON
-0.72

Profitability

Gross Margin
BFRI
64.41%
TNON
59.79%
Operating Margin
BFRI
-89.84%
TNON
-193.52%
Profit Margin
BFRI
-47.28%
TNON
0.0%
ROE
BFRI
-1191.73%
TNON
-228.06%
ROA
BFRI
-64.91%
TNON
-72.88%

Growth

Revenue Growth
BFRI
-22.5%
TNON
92.3%
Earnings Growth
BFRI
--
TNON
--

Financial Health

Debt/Equity
BFRI
--
TNON
0.03
Current Ratio
BFRI
1.15
TNON
2.11
Quick Ratio
BFRI
0.51
TNON
1.7

Dividends

Dividend Yield
BFRI
--
TNON
--
Payout Ratio
BFRI
0.0%
TNON
0.0%

AI Verdict

BFRI BEARISH

BFRI exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of Altman Z-Score data, which raises red flags for potential bankruptcy risk. The company reports massive losses with a -47.28% profit margin, negative ROE (-1191.73%), and declining revenue (YoY -22.50%). Despite a strong gross margin (64.41%), operational inefficiencies and negative cash flows undermine sustainability. The stock trades at a deep discount (Price/Sales: 0.27), but this is not a value signal—rather, it reflects deteriorating fundamentals and investor skepticism. Analysts' 'strong_buy' recommendation appears disconnected from the underlying data.

Strengths
High gross margin (64.41%) suggests potential pricing power or low production costs
Recent 1-month price increase (+3.1%) indicates short-term momentum
Analyst consensus is 'strong_buy' despite poor fundamentals, suggesting potential catalyst expectations
Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational performance
Negative ROE (-1191.73%) and ROA (-64.91%) signal severe capital inefficiency and loss of shareholder value
Consistent earnings misses in the last 4 quarters (0/4 beats, average surprise -88.35%) reflect deteriorating execution
TNON BEARISH

TNON exhibits critical financial fragility with a Piotroski F-Score of 1/9, signaling severe weakness in profitability and operational efficiency. While the company shows impressive top-line momentum with 92.3% YoY revenue growth and maintains a low debt profile, these are overshadowed by a catastrophic -193.52% operating margin and a -228.06% ROE. The long-term price performance is devastating, with a near 100% loss over 5 years, suggesting a failed historical value proposition. Despite optimistic analyst price targets, the deterministic health metrics indicate a high risk of continued equity erosion.

Strengths
Strong YoY revenue growth of 92.30%
High gross margin of 59.79% indicating product value
Very low leverage with a Debt/Equity ratio of 0.03
Risks
Critical financial health as evidenced by Piotroski F-Score of 1/9
Severe operational losses with an operating margin of -193.52%
Extreme equity erosion indicated by ROE of -228.06%

Compare Another Pair

BFRI vs TNON: Head-to-Head Comparison

This page compares Biofrontera Inc. (BFRI) and Tenon Medical, Inc. (TNON) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile